Xoma’s New Business Strategy Emphasizes Proprietary Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.
You may also be interested in...
Xoma Restructures, Focuses On Diabetes Trials
Antibody developer reluctantly releases HCD122 to Novartis for cash now and royalties later.
Xoma Restructures, Focuses On Diabetes Trials
Antibody developer reluctantly releases HCD122 to Novartis for cash now and royalties later.
Pfizer Cash Helps Boost Xoma’s 2007 Revenue
Position is strong as type 2 diabetes candidate advances.